NCT07198074 2026-05-27Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial CancerNational Cancer Institute (NCI)Phase 3 Recruiting255 enrolled